Skip to main content

Mydriasis

4
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Opus Genetics
Opus GeneticsNC - Raleigh
4 programs
1
3
Phentolamine Ophthalmic Solution 0.75%Phase 31 trial
Phentolamine Ophthalmic Solution 0.75%Phase 31 trial
Phentolamine Ophthalmic Solution 0.75%Phase 31 trial
Phentolamine Mesylate Ophthalmic Solution 1%Phase 21 trial
Active Trials
NCT04024891Completed32Est. Sep 2019
NCT04620213Completed185Est. Mar 2021
NCT05134974Completed368Est. Mar 2022
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Opus GeneticsPhentolamine Ophthalmic Solution 0.75%
Opus GeneticsPhentolamine Ophthalmic Solution 0.75%
Opus GeneticsPhentolamine Ophthalmic Solution 0.75%
Opus GeneticsPhentolamine Mesylate Ophthalmic Solution 1%

Clinical Trials (4)

Total enrollment: 608 patients across 4 trials

NCT05223478Opus GeneticsPhentolamine Ophthalmic Solution 0.75%

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

Start: Dec 2021Est. completion: Apr 202223 patients
Phase 3Completed
NCT05134974Opus GeneticsPhentolamine Ophthalmic Solution 0.75%

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Start: Nov 2021Est. completion: Mar 2022368 patients
Phase 3Completed
NCT04620213Opus GeneticsPhentolamine Ophthalmic Solution 0.75%

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Start: Nov 2020Est. completion: Mar 2021185 patients
Phase 3Completed
NCT04024891Opus GeneticsPhentolamine Mesylate Ophthalmic Solution 1%

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Start: Aug 2019Est. completion: Sep 201932 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.